Natural immune activators and foods and beverages for natural immune activation.

Abstract

We provide an innate immune activator containing active ingredients derived from bacteria. [Solution] The innate immune activator contains as an active ingredient a component derived from a Bacteroides bacterium, including at least one selected from the group consisting of Bacteroides ovatus, Bacteroides tethaotaomicron, and Bacteroides uniformis. The component derived from a Bacteroides bacterium may include at least one selected from the group consisting of live Bacteroides cells, dead Bacteroides cells, and processed products thereof.

Description

[Technical Field]

[0001] This invention relates to an innate immune activator and a food and beverage for activating innate immune function. [Background technology]

[0002] Mammals, including humans, possess both an innate immune system and an adaptive immune system. For example, Patent Document 1 describes that certain lactic acid bacteria have the ability to activate the innate immune system. Furthermore, Patent Documents 2 and 3 suggest that certain strains of the genus Bacteroides, which are intestinal bacteria, may be involved in the adaptive immune system.

[0003] Here, Patent Document 4 proposes a method for screening antibacterial compounds using silkworm larvae that possess only an innate immune mechanism. Furthermore, Non-Patent Document 1 suggests that acute oral toxicity tests using silkworm larvae can yield results similar to those obtained in acute toxicity tests using mammals. [Prior art documents] [Patent Documents]

[0004] [Patent Document 1] International Publication No. 2015 / 056770 [Patent Document 2] Special Publication No. 2020-503862 [Patent Document 3] International Publication No. 2022 / 050082 [Patent Document 4] Japanese Patent Publication No. 2007-327964 [Non-patent literature]

[0005] [Non-Patent Document 1] Drug Discoveries & Therapeutics. 2016; 10(1):24-29. [Overview of the Initiative] [Problems that the invention aims to solve]

[0006] One aspect of the present invention aims to provide an innate immune activator and a food or beverage for activating innate immunity, both containing an active ingredient derived from bacteria. [Means for solving the problem]

[0007] The first embodiment is an innate immune activator containing as an active ingredient a component derived from a Bacteroides bacterium, including at least one selected from the group consisting of Bacteroides ovatus, Bacteroides tethaiotaomicron, and Bacteroides uniformis.

[0008] In one embodiment, the component derived from Bacteroides bacteria may include at least one selected from the group consisting of live Bacteroides bacteria, dead Bacteroides bacteria, and processed products thereof. The processed product may also include at least one processed product selected from the group consisting of Bacteroides cultures, concentrates, dried products, liquefied products, diluted products, crushed products, sterilized products, fermented products, frozen products, and extracts.

[0009] The second embodiment is a food or beverage for activating innate immunity, which contains as an active ingredient a component derived from a Bacteroides bacterium, including at least one selected from the group consisting of Bacteroides ovatus, Bacteroides tethaiotaomicron, and Bacteroides uniformis.

[0010] In one embodiment, the component derived from Bacteroides bacteria may include at least one selected from the group consisting of live Bacteroides bacteria, dead Bacteroides bacteria, and processed products thereof. The processed product may also include at least one processed product selected from the group consisting of Bacteroides cultures, concentrates, dried products, liquefied products, diluted products, crushed products, sterilized products, fermented products, frozen products, and freeze-dried products. [Effects of the Invention]

[0011] According to one aspect of the present invention, it is possible to provide an innate immune activator containing an active ingredient derived from bacteria, and a food or beverage for activating innate immunity. [Modes for carrying out the invention]

[0012] In this specification, the term "process" includes not only independent processes but also processes that cannot be clearly distinguished from other processes, as long as their intended purpose is achieved. Furthermore, the content of each component in a composition refers to the total amount of multiple substances present in the composition, unless otherwise specified, if multiple substances corresponding to each component exist in the composition. In addition, the upper and lower limits of the numerical ranges described herein can be arbitrarily selected and combined from the numerical values ​​exemplified as numerical ranges. Embodiments of the present invention will now be described in detail. However, the embodiments shown below are examples of innate immune activators and foods and beverages for innate immune activation that embody the technical concept of the present invention, and the present invention is not limited to the innate immune activators and foods and beverages for innate immune activation shown below.

[0013] Natural Immunity Activator Innate immunity activators contain components derived from Bacteroides bacteria as active ingredients. By containing active ingredients derived from Bacteroides bacteria, at least the innate immune system of an organism is activated, thereby improving the organism's resistance to pathogenic bacteria, for example. The Bacteroides bacteria from which the active ingredients are derived may be bacteria derived from the human intestine, and may include at least one species selected from the group consisting of Bacteroides ovatus, Bacteroides tethaotaomicron, and Bacteroides uniformis.

[0014] The immune mechanisms possessed by organisms include innate immune mechanisms and acquired immune mechanisms. Innate immunity is an immune mechanism present in primitive organisms and is borne by immune cells, also called phagocytes, such as neutrophils and macrophages. The immune cells responsible for innate immunity have receptors that recognize various molecules possessed by microorganisms and the like, and thereby quickly react to microorganisms and the like to try to eliminate them. On the other hand, acquired immunity is borne by lymphocytes such as T cells (cytotoxic T cells, helper T cells) and B cells, and is a mechanism that specifically recognizes and remembers infected microorganisms and the like, and effectively eliminates them during reinfection. Innate immunity can enhance acquired immunity by activating immune cells called dendritic cells, and the activated dendritic cells take in and digest microorganisms and the like and present their components to T cells. An innate immune activator can at least activate the innate immune mechanism, and may also activate the acquired immune mechanism at the same time. The details of the mechanism by which the innate immune activator activates innate immunity are unknown.

[0015] Activation of innate immunity by an innate immune activator can be evaluated, for example, using an organism having only an innate immune mechanism. The organism having only an innate immune mechanism may be, for example, an insect, or may be a silkworm larva. For a method of evaluating the activation of innate immunity using a silkworm larva, reference can be made to, for example, the description in JP-A-2007-327964. Specifically, for example, by using an organism having only an innate immune mechanism as an infection model, infecting it with a pathogenic microorganism, and evaluating the effect of administering a test sample on the infection model, the activation of innate immunity by the test sample in the infection model can be evaluated.

[0016] Here, "pathogenic microorganism" means a microorganism having the ability to infect a host and cause lesions. The pathogenic microorganism may be any microorganism that can infect the administration target of the innate immune activator, and it may be a Gram-negative bacterium or a Gram-positive bacterium. Examples of Gram-negative bacteria include Pseudomonas aeruginosa, Vibrio cholerae, pathogenic Escherichia coli (O-157), etc. Examples of Gram-positive bacteria include Staphylococcus aureus. However, pathogenic microorganisms are not limited to these. For example, silkworm larvae can infect not only Gram-negative bacteria but also Gram-positive bacteria, and thus can be suitably used for evaluating the activation of innate immunity.

[0017] Infection of the pathogenic microorganism model can be performed by, for example, administration methods of pathogenic microorganisms such as intraperitoneal administration, injection into the blood, addition to feed (food), injection into the intestine, etc. The dosage of the pathogenic microorganism administered to the infection model may vary depending on the pathogenic microorganism, the infection model, the type of test sample, etc. Generally, the pathogenic microorganism can be administered as a dilution solution from the culture solution with the highest density that can be cultured to about one-tenth of it. When using the larvae of organisms belonging to insects as the host, for example, about 0.05 ml of the bacterial solution can be injected from the leg into the blood. 4 When using the larvae of organisms belonging to insects as the host, for example, about 0.05 ml of the bacterial solution can be injected from the leg into the blood.

[0018] The evaluation of the activation of innate immunity is performed by evaluating the degree of infection symptoms or survival in an organism having an innate immune mechanism to which a pathogenic microorganism has been administered. Examples of the infection symptoms to be evaluated include, for example, an increase in the number of pathogenic microorganisms in the infection model individual, a decrease in the body weight of the infection model or an inhibition of the increase in the body weight of the infection model, a decrease in the amount of antibacterial substances in the blood of the infection model, a deficiency of the immune function of the infection model, a decrease in various enzyme activities in the body fluids and internal organs of the infection model, etc. If the infection model is the larvae of an insect, for example, it may be evaluated by not molting into older larvae or not becoming a pupa or an adult. In addition to the infection symptoms, the degree of survival of the infection model may be evaluated. Examples of the degree of survival include the survival rate and the survival period.

[0019] The innate immune activator may have an infection-preventive effect against pathogenic microorganisms, an infection-suppressing effect against pathogenic microorganisms, an effect that assists in recovery from infectious diseases against pathogenic microorganisms, or an infection-protective or infection-suppressing effect. The pathogenic microorganisms may include at least one of Gram-negative bacteria and Gram-positive bacteria, and may include at least one selected from the group consisting of Pseudomonas aeruginosa, Vibrio cholerae, pathogenic Escherichia coli, and Staphylococcus aureus.

[0020] The Bacteroides-derived component included as an active ingredient in the innate immunity activator may contain at least one selected from the group consisting of live Bacteroides cells, dead Bacteroides cells, and processed products thereof. Examples of live Bacteroides cells include wet cells and dried cells. Dead Bacteroides cells may be obtained by heat treatment, crushing treatment, pressurization treatment, radiation treatment, or chemical treatment of the cells. In other words, the dead cells may be processed products of live Bacteroides cells. The heat treatment conditions are not particularly limited as long as they kill the cells, and generally sufficient results can be obtained by heating at 110°C to 125°C for 15 to 25 minutes. The heat treatment method is not particularly limited. The crushing treatment is not particularly limited as long as it kills the cells, and may be known treatments such as physical treatment, chemical treatment, enzymatic treatment, or autolysis. Physical processing can be carried out using, for example, homogenizers, ball mills, bead mills, dyno mills, planetary mills, jet mills, French presses, cell disruptors, and filter filtration. Physical processing may be carried out wet (processing in the state of bacterial cell suspension) or dry (processing in the state of bacterial cell powder).

[0021] Examples of processed products of live or dead Bacteroides bacteria (hereinafter also referred to as "processed bacterial products") include cultures, concentrates, dried products, liquefied products, diluted products, crushed products, sterilized products, fermented products, frozen products, and extracts of Bacteroides bacteria. Components derived from Bacteroides bacteria may include at least one processed product selected from the group consisting of these. Examples of dried products include freeze-dried products, spray-dried products, drum-dried products, and vacuum-dried products. Extracts may be extracts obtained by extracting Bacteroides bacteria or their processed products in a liquid medium, or concentrated or dried products thereof.

[0022] The Bacteroides species from which the active ingredients of innate immune activators are derived are well-known and can be characterized based on known mycological properties, such as those described in Burgess' Manual of Bacteriology Vol. 4 (1989). The Bacteroides species can be isolated from the intestines of mammals (e.g., humans, monkeys, chimpanzees, cattle, horses, pigs, sheep, dogs, cats, mice, rats, etc.), and preferably from the intestines of humans.

[0023] The Bacteroides species from which the active ingredient of the innate immune activator is derived may be Bacteroides species derived from the human gut, and may include at least one species selected from the group consisting of Bacteroides ovatus, Bacteroides tethaiotaomicron, and Bacteroides uniformis. Examples of Bacteroides ovatus include strain ATCC8483, strain CCUG4943, strain CIP103756, strain DSM1896, and strain NCTC11153. The Bacteroides ovatus may be the reference strain JCM5824. The reference strain is registered and stored at the Microbial Materials Development Laboratory, BioResource Center, RIKEN (3-1-1 Takanodai, Tsukuba, Ibaraki 305-0074, Japan). Examples of Bacteroides tetaiotaomicron include strains ATCC29148, CCUG10774, CIP104206, DSM2079, and NCTC10582. Bacteroides tetaiotaomicron may be the reference strain JCM5827. Examples of Bacteroides uniformis include strains ATCC8492, CCUG4942, CIP103695, DSM6597, NCTC13054, JCM5828, CP3585, and CP3586. Preferably, these are strains JCM5828, CP3585, and CP3586. Strain JCM5828 is the reference strain. Strains CP3585 and CP3586 were internationally deposited on August 25, 2017, with the Patent Microorganism Depositary Center of the National Institute of Technology and Evaluation (NITE) (Room 122, 2-5-8 Kazusa-Kamatari, Kisarazu City, Chiba Prefecture 292-0818, Japan) under accession numbers NITE BP-02536 and NITE BP-02537.

[0024] Bacteroides bacteria can be cultured using conventional culture media and conditions capable of culturing Bacteroides bacteria, and then harvested to be used as an active ingredient in innate immune activators. The culture medium can be any medium capable of culturing Bacteroides bacteria and is not particularly limited. Examples of culture media include: as a carbon source, glucose, fructose, galactose, maltose, lactose, cellobiose, sucrose, rhamnose, amygdalin, esculin, salicin, melibiose, trehalose, L-arabinose, ribose, D-xylose, inulin, raffinose, starch, molasses, etc.; as a nitrogen source, inorganic ammonium salts such as ammonium sulfate and ammonium nitrate, urea, amino acids, meat extract, yeast extract, polypeptone, organic nitrogen-containing substances such as protein hydrolysates, etc.; and as inorganic salts, magnesium sulfate, potassium dihydrogen phosphate, potassium tartrate, zinc sulfate, magnesium sulfate, copper sulfate, calcium chloride, iron chloride, manganese chloride, etc. Known culture media suitable for culturing Bacteroides bacteria (e.g., NBGT medium, BL medium, GAM medium, etc.) can be used. The culture medium may be a liquid medium, or, if necessary, a solid medium or semi-solid medium to which agar or gelatin has been added.

[0025] The culture can be carried out under anaerobic conditions at a temperature of 20°C to 50°C, preferably 25°C to 45°C, and more preferably 35°C to 37°C. "Anaerobic conditions" means an environment with low oxygen levels sufficient for the growth of Bacteroides bacteria. For example, anaerobic conditions can be achieved using an anaerobic chamber, anaerobic box, sealed container or culture vessel containing an oxygen absorber, etc.

[0026] Culture can be carried out in any format, such as static culture, shaking culture, or tank culture, and there are no particular restrictions on the culture time, but it can range from, for example, 3 hours to 7 days.

[0027] After culturing, the resulting culture may be used as is, or the Bacteroides bacteria may be purified or crudely purified from the culture before use. Purification or crude purification of the bacterial cells from the culture can be carried out by any means, such as centrifugation or filtration.

[0028] The form of the innate immune activator is not particularly limited and may be in the form of a pharmaceutical product, quasi-drug, etc. The dosage form may be an orally administered preparation such as a tablet, pill, capsule, granule, powder, lozenge, syrup, or liquid. These preparations can be manufactured according to known methods using excipients, lubricants, binders, disintegrants, stabilizers, flavoring agents, diluents, coating agents, and other optional additives.

[0029] Examples of excipients include lactose, sucrose, glucose, mannitol, sorbitol, corn starch, potato starch, crystalline cellulose, acacia gum, dextran, dextrin, pullulan, light anhydrous silicic acid, synthetic aluminum silicate, calcium carbonate, calcium hydrogen phosphate, etc. Examples of lubricants include stearic acid, calcium stearate, magnesium stearate, talc, colloidal silica, etc. Examples of binders include hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, macrogol, etc. Examples of disintegrants include low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, calcium carboxymethylcellulose, carboxymethyl starch, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, etc. Examples of stabilizers include methylparaben, propylparaben, benzyl alcohol, etc. Flavoring and deodorizing agents are appropriately selected from commonly used sweeteners, acidulants, flavorings, etc.

[0030] Innate immune activators can also be formulated as food or beverages such as regular foods, health foods, supplements, nutritional supplements, health supplements, functional foods (including foods with functional claims), health functional foods, foods for specified health uses, foods for special dietary uses, nutrient function foods, fortified foods, and nutritional adjustment foods. In other words, this embodiment encompasses food and beverages for activating innate immunity.

[0031] Food and beverages may be composed of components derived from Bacteroides bacteria, and may be composed of these components added to raw materials in the manufacturing process. Specific examples of food and beverages include supplements (tablets, capsules, etc.), soft drinks, fruit juices, milk, processed milk, milk beverages, fermented milk, dairy products such as yogurt and cheese, egg products such as mayonnaise, confectionery such as jelly, candy, gummies, gum, biscuits, crackers, and butter cakes, and bread. Furthermore, components derived from Bacteroides bacteria may be incorporated into livestock feed, or added to raw materials in the feed manufacturing process to constitute the feed.

[0032] In the manufacture of food and beverages, other food ingredients, namely various carbohydrates, emulsifiers, thickeners, sweeteners, acidulants, flavorings, amino acids, fruit juices, etc., may be added as appropriate. Specifically, sugars such as sucrose, isomerized sugar, glucose, fructose, palatinose, trehalose, lactose, and xylose; sugar alcohols such as sorbitol, xylitol, erythritol, lactitol, palatinose, reduced starch syrup, and reduced maltose syrup; high-intensity sweeteners such as aspartame, stevia, acesulfame potassium, and sucralose; emulsifiers such as sucrose fatty acid esters, glycerin fatty acid esters, and lecithin; thickeners (stabilizers) such as carrageenan, xanthan gum, guar gum, pectin, and locust bean gum; acidulants such as citric acid, lactic acid, and malic acid; and fruit juices such as lemon juice, orange juice, and berry juices may be added as appropriate. In addition, vitamins such as vitamin A, B vitamins, vitamin C, vitamin D, and vitamin E; and minerals such as calcium, iron, manganese, and zinc may also be added.

[0033] The content of the component derived from the bacteroides bacterium contained in the natural immune activator or the food or drink for activating natural immunity (hereinafter, also collectively referred to as "natural immune activator", etc.) may vary depending on the dosage form and form of the natural immune activator, etc., but for the natural immune activator, etc., it may be, for example, 0.0001% by mass or more and 99% by mass or less, preferably 0.001% by mass or more and 80% by mass or less, more preferably 0.001% by mass or more and 75% by mass or less. For example, the content of the component derived from the bacteroides bacterium contained in the natural immune activator, etc., as the number of cells, per 1 kg of the natural immune activator, etc., is, for example, 1×10 5 or more and 1×10 17 or less, preferably 1×10 6 or more and 1×10 16 or less.

[0034] The subject (test subject) to which the natural immune activator, etc. is administered or ingested includes mammals (e.g., humans, primates (monkeys, chimpanzees, etc.), livestock (cows, horses, pigs, sheep, etc.), pets (dogs, cats, etc.), laboratory animals (mice, rats, etc.)), birds, reptiles, insects, etc., but preferably mammals, particularly preferably humans.

[0035] The dosage or intake amount of the natural immune activator, etc. can adopt any dosage or intake amount according to the age and weight of the subject, the administration route, the number of administrations / intakes, etc. For example, when administered or ingested orally, taking the component derived from the bacteroides bacterium as the number of cells, 1×10 5 or more per kg per day and 1×10 15 or less per kg, preferably 1×10 6 or more per kg per day and 1×10 14 or less per kg, more preferably 1×10 8 or more per kg per day and 1×10 13 or less per kg, and the selected amount can be administered or ingested in one or multiple times (e.g., 2 to 5 times, preferably 2 to 3 times).

[0036] While natural immune activators can produce effects in small amounts and over a short period, they can also be administered or ingested over a long period. For example, natural immune activators can be administered or ingested continuously for periods of one month or more, two months or more, six months or more, one year or more, or even longer, according to the above-mentioned dosage and administration instructions.

[0037] This embodiment includes a method for activating innate immunity, which involves administering innate immunity activators, etc., to a target. The target to which the innate immunity activators, etc., are administered is, for example, a mammal, and mammals include humans. The target may also be a non-human animal. This embodiment also includes the use of components derived from Bacteroides bacteria in the manufacture of innate immunity activators, etc., used for innate immunity activation, the use of components derived from Bacteroides bacteria in a method for activating innate immunity, and components derived from Bacteroides bacteria used in a method for activating innate immunity.

[0038] The invention relating to this disclosure may encompass, for example, the following embodiments: [1] An innate immune activator containing as an active ingredient a component derived from a Bacteroides bacterium, including at least one selected from the group consisting of Bacteroides ovatus, Bacteroides tethaiotaomicron, and Bacteroides uniformis.

[0039] [2] The innate immune activator according to [1], wherein the component derived from Bacteroides bacteria comprises at least one selected from the group consisting of live Bacteroides bacteria, dead Bacteroides bacteria, and processed products thereof.

[0040] [3] The innate immune activator according to [2], comprising at least one processed product selected from the group consisting of cultures, concentrates, dried products, liquefied products, diluted products, crushed products, sterilized products, fermented products, frozen products and extracts of Bacteroides bacteria.

[0041] [4] Food and beverages for activating innate immunity, containing as an active ingredient a component derived from a Bacteroides bacterium, including at least one selected from the group consisting of Bacteroides ovatus, Bacteroides tethaiotaomicron, and Bacteroides uniformis.

[0042] [5] The food or beverage according to [4], wherein the component derived from Bacteroides is selected from the group consisting of live cells of Bacteroides, dead cells of Bacteroides, and processed products thereof.

[0043] [6] The food and beverage according to [5], wherein the processed product comprises at least one processed product selected from the group consisting of cultures, concentrates, dried products, liquefied products, diluted products, crushed products, sterilized products, fermented products, frozen products and freeze-dried products of Bacteroides bacteria. [Examples]

[0044] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples.

[0045] Example 1 The effect of administering components derived from Bacteroides bacteria into the bloodstream to enhance innate immune activity was evaluated as follows.

[0046] Bacteroides ovatus (reference strain JCM5824), Bacteroides tetaiotaomicron (reference strain JCM5827), and Bacteroides uniformis (reference strain JCM5828) were cultured anaerobically overnight in GAM liquid medium, and heat-killed cells were obtained by sterilization at 121°C for 20 minutes. The obtained dead cells were diluted with physiological saline to obtain test samples with the component concentrations shown in Tables 1 to 3.

[0047] Silkworm eggs were purchased from Ehime, Japan, and raised to the fifth instar using the artificial feed Silkmate 2S (Nosan Corporation, Kanagawa, Japan) to prepare fifth-instar silkworm larvae. 50 μl of the test sample was injected intravascularly into each prepared silkworm larva. Six hours after injection, approximately 50 CFU of live Pseudomonas aeruginosa strain PAO1 was inoculated intravascularly into the silkworm larvae. The silkworm larvae were then reared at 37°C, and the number of survivors was counted after 20 hours. The total number of silkworm larvae per group was set to four, and physiological saline was inoculated as the test sample for the negative control. The results are shown in Tables 1 to 4.

[0048] [Table 1]

[0049] [Table 2]

[0050] [Table 3]

[0051] [Table 4]

[0052] As shown in Tables 1 to 3, when test samples containing components derived from Bacteroides bacteria were administered intravascularly to silkworm larvae, they showed high resistance to Pseudomonas aeruginosa and demonstrated a dose-dependent preventive effect against Pseudomonas aeruginosa infection in silkworm larvae. Note that, as shown in Table 4, the ED of each test sample... 50The values ​​were 0.25 μg / kg for Bacteroides ovatus, 0.03 μg / kg for Bacteroides thetaiotaomicron, and 6.0 μg / kg for Bacteroides uniformis. Furthermore, it was confirmed that the survival rate in the negative control group administered with physiological saline was 0 / 4.

[0053] Example 2 The effect of oral administration of components derived from Bacteroides bacteria on improving innate immune activity was evaluated as follows.

[0054] Bacteroides ovatus (reference strain JCM5824), Bacteroides tetaiotaomicron (reference strain JCM5827), and Bacteroides uniformis (reference strain JCM5828) were cultured anaerobically overnight in GAM liquid medium, and heat-killed cells were obtained by sterilization at 121°C for 20 minutes. The obtained heat-killed cells were mixed with 5g of artificial feed Silkmate 2S (Nosan Corporation, Kanagawa, Japan) at the amounts shown in Table 5, and the test feed was fed to 5th instar silkworm larvae and allowed to freely consume overnight, and the amount of remaining feed was measured. Subsequently, approximately 50 CFU of live Pseudomonas aeruginosa (PAO1 strain) were inoculated intravascularly. Then, the silkworm larvae were fed the artificial feed and reared at 37°C, and the number of surviving larvae was measured after 20 hours. Each group consisted of 5 silkworms. The control group was fed artificial feed without added heat-killed bacteria, the negative control was inoculated with physiological saline (PBS), and the positive control was inoculated with POA1. The results are shown in Tables 5 and 6.

[0055] [Table 5]

[0056] [Table 6]

[0057] As shown in Tables 5 and 6, oral administration of test samples containing components derived from Bacteroides bacteria to silkworm larvae resulted in high resistance to Pseudomonas aeruginosa infection, confirming a dose-dependent preventive effect against Pseudomonas aeruginosa infection in silkworm larvae.

Claims

1. An innate immune activator containing as an active ingredient a component derived from a Bacteroides bacterium, including at least one species selected from the group consisting of Bacteroides ovatus, Bacteroides tetaiotaomicron, and Bacteroides uniformis.

2. The innate immune activator according to claim 1, wherein the component derived from Bacteroides bacteria comprises at least one selected from the group consisting of live Bacteroides bacteria, dead Bacteroides bacteria, and processed products thereof.

3. The innate immune activator according to claim 2, comprising at least one processed product selected from the group consisting of cultures, concentrates, dried products, liquefied products, diluted products, crushed products, sterilized products, fermented products, frozen products, and extracts of Bacteroides bacteria.

4. Food and beverages for activating natural immunity, containing as an active ingredient a component derived from a Bacteroides bacterium, including at least one species selected from the group consisting of Bacteroides ovatus, Bacteroides tethaiotaomicron, and Bacteroides uniformis.

5. The food or beverage according to claim 4, wherein the component derived from Bacteroides bacteria comprises at least one selected from the group consisting of live Bacteroides bacteria, dead Bacteroides bacteria, and processed products thereof.

6. The food and beverage according to claim 5, wherein the processed product comprises at least one processed product selected from the group consisting of cultures, concentrates, dried products, liquefied products, diluted products, crushed products, sterilized products, fermented products, frozen products, and extracts of Bacteroides bacteria.

Images